Kidney Function Influences Warfarin Responsiveness and Hemorrhagic Complications
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Although management of warfarin is challenging for patients with chronic kidney disease (CKD), no prospective studies have compared response to warfarin among patients with minimal, moderate, and severe CKD. This secondary analysis of a prospective cohort of 578 patients evaluated the influence of kidney function on warfarin dosage, anticoagulation control, and risk for hemorrhagic complications. We adjusted all multivariable regression and proportional hazard analyses for clinical and genetic factors. Patients with severe CKD (estimated GFR <30 ml/min per 1.73 kg/m2) required significantly lower warfarin dosages (P = 0.0002), spent less time with their international normalized ratio within the target range (P = 0.049), and were at a higher risk for overanticoagulation (international normalized ratio >4; P = 0.052), compared with patients with no, mild, or moderate CKD. Patients with severe CKD had a risk for major hemorrhage more than double that of patients with lesser degrees of renal dysfunction (hazard ratio 2.4, 95% confidence interval 1.1 to 5.3). In conclusion, patients with reduced kidney function require lower dosages of warfarin, have poorer control of anticoagulation, and are at a higher risk for major hemorrhage. These observations suggest that warfarin may need to be initiated at a lower dosage and monitored more closely in patients with moderate or severe CKD compared with the general population. Diminished renal function may have implications for a larger proportion of warfarin users than previously estimated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Performing the Exact Test of Hardy-Weinberg Proportion for Multiple Alleles
Guo, S. W., & Thompson, E. A. (1992) · Biometrics · doi:10.2307/2532296 · Cited by 4,880
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study
Fihn, S. D., McDonell, M., Martin, D., Henikoff, J., Vermes, D., Kent, D., White, R. H., & for the Warfarin Optimized Outpatient Follow-up Study Group* (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00005 · Cited by 671
Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz, D. S., Shehab, N., Kegler, S. R., & Richards, C. L. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00006 · Cited by 607
Association of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
CLINICAL AND TOXICOLOGICAL RELEVANCE OF CYP2C9: Drug-Drug Interactions and Pharmacogenetics
Rettie, A. E., & Jones, J. P. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095821 · Cited by 254
Limdi, N., McGwin, G., Goldstein, J., Beasley, T., Arnett, D., Adler, B., Baird, M., & Acton, R. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100290 · Cited by 248
Self-citationAtrial Fibrillation and Morbidity and Mortality in a Cohort of Long-term Hemodialysis Patients
Genovesi, S., Vincenti, A., Rossi, E., Pogliani, D., Acquistapace, I., Stella, A., & Valsecchi, M. G. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.034 · Cited by 215
Cited by
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Brodsky, S. V., Nadasdy, T., Rovin, B. H., Satoskar, A. A., Nadasdy, G. M., Wu, H. M., Bhatt, U. Y., & Hebert, L. A. (2011) · Kidney International · doi:10.1038/ki.2011.44 · Cited by 314
Warfarin in atrial fibrillation patients with moderate chronic kidney disease
Hart, R. G., Pearce, L. A., Asinger, R. W., & Herzog, C. A. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02400311 · Cited by 204
“Our results, however, are consistent with the cohort analysis finding that stage 3 CKD was not an independent predictor of major or minor hemorrhage during warfarin anticoagulation (22).”
BackgroundResultSevere Renal Impairment and Stroke Prevention in Atrial Fibrillation
Marinigh, R., Lane, D. A., & Lip, G. Y. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.12.013 · Cited by 195
Jun, M., James, M. T., Manns, B. J., Quinn, R. R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W. C., Ma, Z., Hemmelgarn, B. R., et al. (2015) · BMJ · doi:10.1136/bmj.h246 · Cited by 143
Roldán, V., Marín, F., Fernández, H., Manzano-Fernández, S., Gallego, P., Valdés, M., Vicente, V., & Lip, G. Y. H. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.045 · Cited by 117
Metadata
- Authors
- Limdi, N. A., Beasley, T. M., Baird, M. F., Goldstein, J. A., McGwin, G., Arnett, D. K., Acton, R. T., & Allon, M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2009-04
- Volume
- 20
- Issue
- 4
- Pages
- 912-921
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2166551141
- Cited by
- 292
- References
- 32
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.